Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 5.3% in March

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,980,000 shares, a growth of 5.3% from the March 15th total of 3,780,000 shares. Based on an average daily volume of 968,700 shares, the days-to-cover ratio is currently 4.1 days. Approximately 4.6% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its position in shares of Humacyte by 17.3% during the second quarter. UBS Asset Management Americas Inc. now owns 15,947 shares of the company’s stock valued at $51,000 after buying an additional 2,347 shares during the period. Legal & General Group Plc grew its holdings in shares of Humacyte by 24.7% during the 2nd quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock worth $55,000 after acquiring an additional 3,364 shares during the period. Susquehanna International Group LLP raised its position in shares of Humacyte by 16.2% in the 1st quarter. Susquehanna International Group LLP now owns 31,367 shares of the company’s stock worth $97,000 after acquiring an additional 4,372 shares in the last quarter. UBS Group AG lifted its stake in shares of Humacyte by 92.0% in the 3rd quarter. UBS Group AG now owns 9,827 shares of the company’s stock valued at $32,000 after purchasing an additional 4,710 shares during the period. Finally, Osaic Holdings Inc. boosted its position in shares of Humacyte by 16.3% during the second quarter. Osaic Holdings Inc. now owns 33,985 shares of the company’s stock valued at $97,000 after purchasing an additional 4,775 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HUMA. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Humacyte in a research report on Monday, April 1st. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price on shares of Humacyte in a report on Tuesday, March 26th. Finally, Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Monday, March 25th.

Humacyte Stock Up 2.0 %

Shares of NASDAQ HUMA opened at $3.12 on Thursday. The company has a market cap of $371.54 million, a price-to-earnings ratio of -2.92 and a beta of 1.46. The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of 1.20. The firm’s fifty day moving average is $3.52 and its 200 day moving average is $2.97. Humacyte has a 52 week low of $1.96 and a 52 week high of $5.60.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period in the previous year, the firm earned ($0.21) EPS. On average, equities research analysts expect that Humacyte will post -0.9 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).